RxDoctor Payments Data

Jyothirmai Bobba

Family Medicine · Kalamazoo, MINPI 1710060066

Payments from drug & device makers

$1,712in general payments, 2019–2025

Across 64 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$522
  • AstraZeneca$194
  • Abbott$154
  • AbbVie$142
  • Merck$142
  • Boehringer Ingelheim$138
  • plus $420 from 10 others

What the payments were for

  • Food & beverage$1,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,712 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$26,096
Medicare patients
123
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$101,006
EliquisApixaban68$59,823
TrulicityDulaglutide32$52,748
MounjaroTirzepatide34$36,356
JanuviaSitagliptin Phosphate17$27,858
OzempicSemaglutide20$25,419
FarxigaDapagliflozin Propanediol16$17,646
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,573
Atorvastatin Calcium387$6,115
Spiriva HandihalerTiotropium Bromide11$5,174
Risedronate Sodium38$4,440
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$4,081
Omeprazole172$4,024
Levothyroxine Sodium276$3,959
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$138$101,00675 claims
Lilly USA, LLCTrulicity, Mounjaro$33$89,10466 claims
PfizerEliquis$63$59,82368 claims
MerckJanuvia$142$27,85817 claims
Novo NordiskOzempic$522$25,41920 claims
AstraZenecaFarxiga$194$17,64616 claims
GSKTrelegy Ellipta$47$16,57317 claims
AbbVieSynthroid$142$1,07815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →